UGXY

Ultragenyx MAA Validation for MPS IIIA Gene Therapy in Europe

Ultragenyx's rebisufligene etisparvovec received EMA validation for a Marketing Authorisation Application, marking the first investigational gene therapy submission for MPS IIIA (Sanfilippo syndrome Type A) in Europe. Validation signals regulatory pathway advancement toward potential commercialisation.